Copper is an indispensable trace element, serving as a cofactor for enzymes involved in respiration, antioxidant defense, and connective tissue formation. Yet when copper homeostasis collapses, the consequences for a cell can be fatal in a way that scientists only began to define in 2022. That year, Peter Tsvetkov and colleagues reported in Science that excess mitochondrial copper binds directly to lipoylated components of the tricarboxylic acid cycle, the enzymatic engine at the heart of mitochondrial metabolism. The resulting accumulation of lipoylated TCA cycle proteins triggers a distinctive form of proteotoxic stress that the authors named cuproptosis, setting it apart from apoptosis, necrosis, and other better-known death programs. Crucially, the process depends on the mitochondrial protein ferredoxin 1, or FDX1, which regulates protein lipoylation through its interaction with the lipoic acid synthase LIAS.

What makes this mechanism so intriguing for liver cancer is a biological paradox. Hepatocellular carcinoma cells frequently exhibit elevated copper metabolism, importing and distributing the metal aggressively to fuel their proliferative demands. But the same dependence appears to raise their vulnerability: when copper overload is pharmacologically forced into the mitochondria, these copper-hungry cells die disproportionately. Earlier work from Tsvetkov’s group had shown that highly lipoylated, mitochondria-rich tumors are especially sensitive to elesclomol, an investigational copper ionophore that ferries copper ions into the mitochondrial interior. Disulfiram, an old alcohol-aversion drug that acts as a copper ionophore, has shown similar copper-dependent toxicity against tumor cells in multiple preclinical models, and recent studies have linked DLAT, a lipoylated enzyme of the pyruvate dehydrogenase complex, to elesclomol sensitivity specifically in hepatocellular carcinoma.

The iron side of the equation is equally consequential. Ferroptosis, first described in 2012, is a form of regulated cell death driven by iron-dependent lipid peroxidation. When the antioxidant systems that normally reduce lipid hydroperoxides falter, particularly the glutathione–glutathione peroxidase 4, or GSH–GPX4, axis, polyunsaturated fatty acids in cellular membranes undergo a radical chain reaction that ruptures the lipid bilayer. The liver, as the body’s principal iron storage and metabolic organ, is exquisitely sensitive to this chemistry. Hepatocellular carcinoma cells, meanwhile, must constantly manage iron influx and oxidative stress to survive, and numerous studies have documented that manipulating iron availability, lipid composition, and antioxidant capacity can tip these cells into ferroptotic death.

The review pays particular attention to the regulatory networks that determine how sensitive a given hepatocellular carcinoma cell is to ferroptosis. Nuclear factor erythroid 2–related factor 2, or NRF2, a master transcriptional regulator of antioxidant responses, emerges as a central node. When NRF2 signaling is active, cells upregulate glutathione synthesis, iron efflux, and a battery of cytoprotective enzymes, effectively raising a shield against lipid peroxidation. FSP1, a ferroptosis suppressor protein that reduces coenzyme Q10 at the plasma membrane, provides a parallel rescue pathway that operates independently of glutathione. Both defenses can be subverted: work from Ren and colleagues showed that overcoming the compensatory elevation of NRF2 rendered hepatocellular carcinoma cells markedly more vulnerable to disulfiram/copper-induced ferroptosis, while other studies have demonstrated that blocking the cystine transporter xCT, which feeds glutathione synthesis, cooperates lethally with copper-driven stress.

It is at this intersection that the review’s central thesis emerges. Copper toxicity and ferroptosis are not isolated programs; they converge on shared metabolic vulnerabilities. Mitochondrial copper overload destabilizes iron-sulfur clusters, the ancient cofactors that support respiratory and repair enzymes, and this destabilization can itself sensitize cells to lipid peroxidation through iron regulatory proteins. More strikingly, glutathione sits at the crossroads of both pathways. The antioxidant tripeptide neutralizes copper-driven oxidative stress on one hand and fuels GPX4-mediated suppression of ferroptosis on the other. Experimental studies in primary liver cancer have shown that ferroptosis inducers enhance cuproptosis triggered by copper ionophores, and that disulfiram/copper treatment consumes glutathione in a way that launches what one team described as a cascade of ferroptosis and cuproptosis when xCT compensation is simultaneously blocked.

The therapeutic implications are substantial. Standard first-line drugs for advanced hepatocellular carcinoma, including sorafenib and lenvatinib, already exert part of their activity through ferroptosis-related mechanisms; lenvatinib, for example, has been shown to induce ferroptosis via fibroblast growth factor receptor-4 inhibition, while sorafenib sensitivity is modulated by metallothioneins and antioxidant pathways. Layering copper ionophores on top of these agents could push tumor cells past a metabolic tipping point that single-agent therapy never reaches. Nanotechnology is accelerating this vision: research groups have developed reactive oxygen species–responsive nanoparticles co-delivering elesclomol and copper together with anti–PD-L1 immunotherapy, as well as injectable hydrogel systems that combine cuproptosis induction with stemness inhibition to overcome lenvatinib resistance. A 2026 study in Antioxidants described a ROS-responsive nanoplatform that targets both cuproptosis and ferroptosis for synergistic therapy against hepatocellular carcinoma, illustrating how rapidly the dual-targeting concept is moving from theory toward experimental implementation.

The tumor microenvironment adds a further dimension of complexity, and opportunity. Both cuproptosis and ferroptosis are immunologically loud forms of cell death: dying cells release damage-associated molecular patterns and oxidized lipids that can stimulate antitumor immunity, and vaccination with early ferroptotic cancer cells has been shown to induce efficient antitumor immune responses. Multiomics and single-cell sequencing analyses have linked cuproptosis signatures to the immunosuppressive architecture of tumors, while ferroptotic tumor cells can enhance the efficacy of checkpoint inhibitors. Yet the picture is not uniformly favorable. Some work has found that disulfiram combined with copper stabilizes PD-L1 in hepatocellular carcinoma, potentially inducing immunosuppression, a reminder that metal-based therapies must be calibrated carefully if they are to synergize with, rather than undermine, immunotherapy. Macrophage polarization, exosome-mediated signaling, and the metabolic state of stromal cells all modulate how these death programs play out in vivo.

The review’s authors are candid about the limits of the current evidence. Direct clinical data demonstrating that pharmacological induction of cuproptosis, or coordinated cuproptosis–ferroptosis targeting, benefits patients with hepatocellular carcinoma are still lacking. Copper chelation trials, trientine-based antiangiogenic strategies, and disulfiram repurposing efforts have generated encouraging preclinical signals, but translating them into validated regimens will require careful attention to dosing, copper delivery, and patient selection. Biomarkers are an urgent need: serum copper, zinc, and metallothionein levels have been proposed as potential biomarkers for hepatocellular carcinoma, and gene-expression signatures built around FDX1, DLAT, ATP7A, and other cuproptosis-related genes are being explored for prognostic and predictive value. Determining which tumors are copper-vulnerable, which rely on NRF2 or FSP1 for ferroptosis resistance, and which harbor metabolic contexts that favor one death program over the other will be essential for rational combination therapy.

Even with these caveats, the synthesis marks a conceptual shift in how liver cancer might be treated. Rather than viewing copper and iron merely as nutrients that tumors consume, the field increasingly regards their homeostatic control as a pair of interlocking kill switches. Disrupting mitochondrial copper handling destabilizes the metabolic core of the cell; dismantling antioxidant defenses unleashes iron-catalyzed membrane destruction; and because glutathione and related systems guard against both threats simultaneously, a single well-designed intervention can pull two levers at once. With combination strategies already showing synergy in preclinical liver cancer models, and nanoparticle delivery platforms maturing quickly, the copper–iron crosstalk framework offers hepatocellular carcinoma research one of its most mechanistically grounded and therapeutically tantalizing frontiers in years.

Subject of Research: Cuproptosis and ferroptosis as coordinated therapeutic targets in hepatocellular carcinoma

Article Title: Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma

Article References: Xie, X., Cao, H., Chen, H., Zhang, S., & Han, Z. (2026). Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma. Medical Oncology, 43(10), Article 268. https://doi.org/10.1007/s12032-026-03399-z

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03399-z

Keywords: cuproptosis, ferroptosis, hepatocellular carcinoma, copper metabolism, iron metabolism, GPX4, NRF2, FDX1, disulfiram, elesclomol, glutathione, targeted therapy

Lung cancer remains one of the deadliest malignancies worldwide, with survival rates stagnating despite advances in chemotherapy, targeted therapy, and immunotherapy. Novel strategies targeting specific vulnerabilities of cancer cells are urgently needed. Artemisinin derivatives, originally extracted from the sweet wormwood plant, have sparked interest for their potent cytotoxic effects beyond malaria, demonstrated in variety of cancers. However, the mechanistic underpinnings of how these compounds induce cell death in lung cancer have been elusive—until now.

The team’s research dissected the biochemical influence of artemisinin derivatives on ferroptosis, an iron-dependent, lipid peroxidation-driven mode of cell death increasingly recognized as a therapeutic target in oncology. By regulating GPX4 (glutathione peroxidase 4), which protects cells from oxidative damage by reducing lipid hydroperoxides, these derivatives appear to manipulate the balance between survival and death in cancer cells. Crucially, the study revealed that the impact of artemisinin-based treatment varies significantly across lung cancer subtypes, underscoring the heterogeneity and complexity embedded within this disease.

Employing sophisticated ex vivo patient-derived tissue cultures, which more faithfully mimic in vivo tumor microenvironments compared to traditional cell lines, the researchers provided robust data illustrating differential susceptibilities to artemisinin-induced ferroptosis. Adenocarcinomas and squamous cell carcinomas of the lung, two major histological subtypes, showed divergent responses in GPX4 expression and subsequent cell viability. This differential regulation hints at subtype-specific vulnerabilities that can be therapeutically exploited with precision.

At the heart of the study lies the enzyme GPX4, a master regulator mitigating ferroptotic cell death by countering lipid peroxidation. Downregulation or inhibition of GPX4 tips the redox homeostasis toward lethal accumulation of peroxidized lipids, selectively killing cancer cells while sparing normal tissue. The research demonstrated that artemisinin derivatives induce variable modulation of GPX4 depending on the lung cancer subtype, a finding that could inform future strategies to sensitize resistant tumors to ferroptosis inducers.

Intriguingly, the work uncovered that not all artemisinin derivatives wield uniform effects—chemical modifications within this drug class alter their capacity to regulate GPX4 and trigger ferroptosis. This nuance raises the prospect of designing derivative-specific therapies tailored to maximize tumor killing while minimizing off-target cytotoxicity. Such a precision pharmacological approach could revolutionize lung cancer treatment landscapes in the near future.

Additionally, the researchers integrated advanced molecular profiling, confirming that artemisinin-induced changes in GPX4 expression coincided with shifts in lipid peroxidation biomarkers and iron metabolism pathways. These corroborative findings substantiate the mechanistic hypothesis that ferroptosis is the predominant mode of cell death invoked by these compounds in patient-derived samples, marking a significant leap toward translational relevance.

Beyond biochemical parameters, the study’s utilization of clinically relevant tissue cultures bridges the gap between laboratory discovery and patient applicability. Traditional cancer cell lines often fail to recapitulate the complexity and heterogeneity of tumors in patients, which hampers drug development. The application of patient-derived cultures not only enhances predictive accuracy for therapeutic responses but also opens possibilities for personalized medicine strategies grounded on individual tumor biology.

This research also spotlights the broader implications of ferroptosis modulation in cancer therapy. Ferroptosis induction circumvents resistance mechanisms that blunt apoptosis, the classical programmed cell death pathway exploited by many drugs. By harnessing ferroptosis, artemisinin derivatives could overcome refractory disease states, a tantalizing prospect amidst the persistent challenge of therapy-resistant lung cancer.

Further exploration will be necessary to translate these findings into clinical protocols, encompassing dosing schemas, combinational regimens, and toxicity profiling. Nonetheless, the molecular insights gained provide a strong rationale for advancing artemisinin derivatives into early-phase clinical trials targeting specific lung cancer subtypes. Enhanced understanding of GPX4 regulation might also catalyze the discovery of novel biomarkers predicting treatment efficacy.

The study’s publication in Cell Death Discovery marks a milestone in cancer pharmacology, expanding the pharmacodynamic repertoire of artemisinin derivatives and illustrating the nuanced interplay between drug chemistry and tumor biology. Given the global burden of lung cancer, these findings could eventually impact millions by fostering more effective, individualized treatment options grounded in ferroptosis biology.

Encouragingly, the data support synergistic potential when combining artemisinin derivatives with other agents targeting complementary pathways, such as iron metabolism modulators or glutathione biosynthesis inhibitors. This polypharmacological strategy could amplify cancer cell vulnerability and mitigate resistance, reinforcing the therapeutic paradigm shift toward multifaceted ferroptosis-centered regimens.

Moreover, the exploration of artemisinin compounds nullifies the old assumption that a drug originally purposed for infectious disease cannot be repurposed successfully in oncology. Their structural versatility and ability to engage multiple cell death pathways spotlight these derivatives as a class of drugs with remarkable translational versatility and clinical potential.

The researchers emphasize that continued investigation is crucial to unravel the detailed molecular cascades linking artemisinin-induced oxidative stress, GPX4 inhibition, and ferroptotic cell demise. Such studies could also identify patient populations most likely to benefit, refining stratification for clinical trials. Personalized medicine stands to gain enormously from these targeted insights.

In conclusion, this landmark study offers a vivid demonstration that artemisinin derivatives wield subtype-specific control over lung cancer cell fate by precisely manipulating GPX4 and ferroptosis. Patient-derived tissue cultures have been instrumental in validating these effects in a clinically relevant context, heralding a strategic shift in lung cancer therapeutics towards ferroptosis modulation. As cancer research accelerates, the therapeutic horizons inspired by this work beckon with real promise for patients confronting lung malignancies.

Subject of Research: Artemisinin derivatives and their effect on cell death mechanisms, specifically ferroptosis via GPX4 regulation, in lung cancer subtypes.

Article Title: Artemisinin derivatives differently affect cell death of lung cancer subtypes by regulating GPX4 in patient-derived tissue cultures.

Article References:
Mölleken, J., Kragl, A., Monecke, A. et al. Artemisinin derivatives differently affect cell death of lung cancer subtypes by regulating GPX4 in patient-derived tissue cultures. Cell Death Discov. 11, 256 (2025). https://doi.org/10.1038/s41420-025-02537-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02537-2